Biogen Inc
Biogen Inc (BIIB) Expected Move
BIIB expected move through Nov 27, 2026 is 4.0%, with 6 days to expiration. The implied range is $239.58 to $259.60, based on the previous trading day's options prices.
Read more
Tracking the BIIB expected move helps you see how far Biogen Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Biogen Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the BIIB expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For BIIB, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The BIIB expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Biogen Inc is unlikely to go.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the BIIB expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Biogen Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about BIIB.
BIIB Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Nov 27, 2026 | 6 | $10.01 | 4.0% | $259.60 | $239.58 |
| Dec 4, 2026 | 13 | $18.35 | 7.4% | $267.94 | $231.24 |
| Dec 11, 2026 | 20 | $27.70 | 11.1% | $277.29 | $221.89 |
| Dec 18, 2026 | 27 | $34.70 | 13.9% | $284.29 | $214.89 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →